Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy

Lower Urinary Tract Symptoms
Tomohiro MatsuoHideki Sakai

Abstract

Mirabegron is widely considered as an effective and safe drug for patients with overactive bladder (OAB). However, there is no evidence regarding the efficacy of mirabegron in human T cell lymphotropic virus-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients with OAB symptoms. The aim of the present study was to clarify the efficacy of mirabegron in HAM/TSP patients with OAB symptoms. The present study evaluated the efficacy of mirabegron treatment (50 mg, once daily) in nineteen HAM/TSP patients with OAB symptoms by assessing subjective symptoms using the overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) before and 12 weeks after administration. Voided volume (VV), maximum flow rate (Qmax ), and post-void residual (PVR) urine volume were evaluated as objective symptoms. Mirabegron treatment improved OABSS in terms of night-time frequency, urgency, and total score (P < .001). In addition, on the IPSS, mirabegron therapy improved urgency, nocturia, storage symptoms (Questions 2, 4 and 7 on the IPSS), as well as the total score (P < .001). The quality of life (QoL) on the IPSS also improved after treatment (P < .001). However, there were no significant changes i...Continue Reading

References

May 3, 1986·Lancet·M OsameM Tara
May 1, 1993·AIDS Research and Human Retroviruses·G de Thé, R Bomford
Mar 13, 2001·Annual Review of Immunology·M Yoshida
May 10, 2007·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Neviton M CastroEdgar M Carvalho
May 17, 2007·Clinics·Paulo OliveiraEdgar M Carvalho
Feb 9, 2008·Journal of the Neurological Sciences·Mariana Garcia CrodaJorge Casseb
Apr 19, 2012·Arquivos de neuro-psiquiatria·Davi Tanajura CostaMarshall Jay Glesby
Aug 6, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Christopher R ChappleVik Khullar
Sep 18, 2014·Revista Da Sociedade Brasileira De Medicina Tropical·José Abraão Carneiro NetoEdgar Marcelino de Carvalho
Nov 6, 2015·BMC Musculoskeletal Disorders·Hideki NakamuraAtsushi Kawakami
May 27, 2016·Orphanet Journal of Rare Diseases·Ariella L G Coler-ReillyYoshihisa Yamano
Dec 8, 2016·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Daniela Assis do ValeKarem López Ortega

❮ Previous
Next ❯

Software Mentioned

JMP

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.